ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors.Daniel H. Palmer, Sarah P. Blagden, Jemma Proudfoot-Jones et al.|Journal of Clinical Oncology|2024Cited by 4
354P NUC-3373, a ProTide transformation of 5-FU, in combination with oxaliplatin (NUFOX) or irinotecan (NUFIRI) in patients with advanced colorectal cancer (CRC) (NuTide:302)Andrew L. Coveler, T. R. J. Evans, Aglaia Skolariki et al.|Annals of Oncology|2022Cited by 3
719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Sarah P. Blagden et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 studySarah P. Blagden, Elizabeth Ruth Plummer, Stefan N. Symeonides et al.|Molecular Cancer Therapeutics|2023Cited by 1
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)Khurum Khan, T.R. Jeffry Evans, Uma Mukherjee et al.|Molecular Cancer Therapeutics|2023Cited by 1